| Establishing Mutual Growth Momentum Via Technology Exchange, Joint Research Collaboration, and Leveraging Global Networks.
(From left) Kwunho Jung, CEO of JNPMEDI; Donhaeng Lee, CEO of NextBioMedical.
JNPMEDI announced on the 28th that it has signed a Memorandum of Understanding (MOU) with NextBioMedical, an innovative therapeutic materials development and export company, to enhance global competitiveness and technical cooperation.
Both organizations plan to share expertise and resources related to clinical trials and collaborate to improve the quality and efficiency of these trials. JNPMEDI will support NextBioMedical's global clinical and market entry efforts by providing professional services, including the operation of the Maven Clinical Cloud solution, global Project Management Office (PMO) operations, and license strategy formulation.
Kwunho Jung, CEO of JNPMEDI, stated, "We expect our expertise to increase the success rate and efficiency of clinical trials for NextBioMedical's medical devices. Through continuous collaboration, we aim to present advanced solutions throughout the entire process of clinical trials and new product development, thereby creating high value in the pharmaceutical and biotech fields."
Donhaeng Lee, CEO of NextBioMedical, remarked, "The collaboration with JNPMEDI, which possesses high-level digital technology and an extensive global network, will greatly aid in enhancing our global competitiveness. We hope to establish mutual growth momentum through the close cooperation between the two companies."
(From left) JNPMEDI: Jueun Kim, Global PL; Seungmi Lee, Executive Director; Jaehyun Lee, COS; Kwunho Jung, CEO / NextBioMedical: Donhaeng Lee, CEO; Choongryul Choi, Vice President; Jeonga Park, Manager; Jinhui Maeng, Senior Researcher.
| Establishing Mutual Growth Momentum Via Technology Exchange, Joint Research Collaboration, and Leveraging Global Networks.
(From left) Kwunho Jung, CEO of JNPMEDI; Donhaeng Lee, CEO of NextBioMedical.
JNPMEDI announced on the 28th that it has signed a Memorandum of Understanding (MOU) with NextBioMedical, an innovative therapeutic materials development and export company, to enhance global competitiveness and technical cooperation.
Both organizations plan to share expertise and resources related to clinical trials and collaborate to improve the quality and efficiency of these trials. JNPMEDI will support NextBioMedical's global clinical and market entry efforts by providing professional services, including the operation of the Maven Clinical Cloud solution, global Project Management Office (PMO) operations, and license strategy formulation.
Kwunho Jung, CEO of JNPMEDI, stated, "We expect our expertise to increase the success rate and efficiency of clinical trials for NextBioMedical's medical devices. Through continuous collaboration, we aim to present advanced solutions throughout the entire process of clinical trials and new product development, thereby creating high value in the pharmaceutical and biotech fields."
Donhaeng Lee, CEO of NextBioMedical, remarked, "The collaboration with JNPMEDI, which possesses high-level digital technology and an extensive global network, will greatly aid in enhancing our global competitiveness. We hope to establish mutual growth momentum through the close cooperation between the two companies."
(From left) JNPMEDI: Jueun Kim, Global PL; Seungmi Lee, Executive Director; Jaehyun Lee, COS; Kwunho Jung, CEO / NextBioMedical: Donhaeng Lee, CEO; Choongryul Choi, Vice President; Jeonga Park, Manager; Jinhui Maeng, Senior Researcher.